Pulmonem Inc. is a pioneering biotechnology company dedicated to advancing therapeutic solutions for Acute Respiratory Distress Syndrome (ARDS). Pulmonem has obtained Investigational New Drug (IND) approval for a Phase 3 clinical trial in the United States (FDA) and Canada, with plans underway to secure an IND in India.
Pulmonem is also pursuing solutions for the pediatric market, as well as alternative delivery systems, such as nasal sprays and liquids.
Shifting our focus from COVID-19 to ARDS
Pulmonem is shifting its primary focus from COVID-19 to Acute Respiratory Distress Syndrome (ARDS) in response to evolving market demands and scientific advancements. This strategic decision is driven by promising research and the substantial unmet medical need in ARDS, presenting a significant opportunity for Pulmonem to make a meaningful impact.
COVID-19 infection is only one of the multiple causes of ARDS, which is a severe condition characterized by the rapid onset of widespread inflammation in the lungs, often leading to respiratory failure. The current treatment options for ARDS are limited and primarily supportive. This underscores the urgent need for innovative therapeutic interventions. The Yale medicine website reports that “In fact, in the United States, about 190,000 Americans are diagnosed with ARDS each year” and that “Even with treatment, about 25% to 40% of people with ARDS do not survive”. By pivoting towards ARDS, Pulmonem aims to leverage its expertise and resources to develop novel treatments to mitigate this critical respiratory medicine gap.
Acute Respiratory Distress Syndrome (ARDS)
ARDS is a severe lung condition often triggered by infections like pneumonia, sepsis, or other serious blood infections. Common infections that can lead to ARDS include:
- Flu (influenza)
- Respiratory syncytial virus
- SARS-CoV-2, the virus responsible for COVID-19
Currently, There is No Cure for ARDS
Treatments available are limited to supporting patients while their lungs heal. These treatments or procedures are not always suitable for every ARDS patients. They consist of:
- Ventilator support
- Prone positioning (complicated task and some patients are too sick for this treatment)
- Sedation/Paralytics medications (These medications have significant side effects and their risks and benefits must be continuously monitored)
- Diuretics medication (must be done carefully, because too much fluid removal can lower blood pressure and lead to kidney problems.)
- Extracorporeal membrane oxygenation (ECMO) (very complicated treatment that takes blood outside of your body and pumps it through a membrane that adds oxygen, removes carbon dioxide and then returns the blood to your body. This is a high-risk therapy with many potential complications.)
Market Size and Growth
The global market for ARDS treatments is projected to grow from USD 3.26 billion in 2024 to USD 4.30 billion by 2029, at a CAGR of 5.65% (Source: Mordor Insights™).
Our Solution
Pulmonem aims to leverage its expertise and resources to develop novel treatments that address this critical gap in respiratory medicine.
At the heart of Pulmonem’s pipeline is PULM-001, a revolutionary anti-inflammatory, immuno-modulator, and antibacterial drug designed to combat infectious diseases, including malaria, lupus, HIV, and pneumocystis pneumonia. Published studies have shown the effectiveness of PULM-001 in significantly enhancing overall patient survival rates by mitigating symptoms, reducing complications and hospitalizations, and curbing ICU admissions, mechanical ventilation, and mortality rates associated with ARDS.
Advantages of PULM-001:
- Improved Survival Rates by mitigating ARDS symptoms
- Reduction in Complications and
- HospitalizationsDecreased ICU Admissions, Mechanical Ventilation, and Mortality for ARDS patients
Management Team
Houfar Sekhavat, MD
Founder and Chairman
Ophthalmologist, serial entrepreneur and innovator. Founder of Triple Hair Inc. (hair growth therapies) and Hexiris Pharma Inc. (treatment of glaucoma).
Jean-Philippe Gravel, MBA
Co-Founder and Chief Operating Officer
Over 15 years of experience in management and business development, mainly with medical, pharmaceutical and natural health product companies. President and CEO of Triple Hair Inc.
Guy Chamberland, Ph.D.
CEO
Over 27 years of experience in management, drug development and regulatory affairs with medical, pharmaceutical and natural health product companies.
Denis Albert, CPA, CA
Co-Founder
Managing partner at Boudreau Albert Savoie & Associates, in charge of operations, strategic direction and client relationships, with over 21 years of experience in accounting, tax planning and business-related matters, including tax and financial restructuring, financing, business sales and acquisitions.
Awdah Arraf, Ph.D.
Co-Founder
Patent and innovation strategy specialist with over 20 years of experience helping tech and pharma start-ups establish and exploit patent portfolios. Engaged in science and technology, she dedicates her skills to organizations with profound products and services that will ultimately contribute to enhancing the lifestyle and wellbeing of individuals globally.
Chanele Dumontier, CPA
Chief Financial Officer
Extensive experience in finance and accounting in leading international companies with a focus on growth strategies, mergers and acquisitions and partnership development.
Satish Asotra, Ph.D., MBA
Chief Manufacturing and Regulatory Officer
Senior executive and strategic leader with a proven track record of driving pharmaceutical development, innovation and process improvement with 25 years of experience, including more than 12 years in topical and dermatological product development, with Avicanna, AHI, Accucaps, Odan Laboratories and Taro Pharmaceuticals.
Georges H. Lavanchy
Vice President, International Development
Entrepreneur with international management experience in various fields for over 30 years. Excellent knowledge of European markets and their business practices. Searching for innovative products to be developed.
Avraham Yacobi, Ph.D., M.Pharm.
Principal Scientific Advisor
Expert consultant with over 35 years of experience in pharmaceutical R&D and regulatory affairs. Previously served as President of R&D at Taro Pharmaceuticals USA for 16 years, and as Senior VP and Officer at Taro Pharmaceutical Industries. Currently President of DOLE Pharma, LLC and Founder and Scientific Advisor to BluPax Pharma.
Latest News
Looking to Invest?
Interested in investing or participating in the Clinical Trial?
Please complete the form below or email us at info@pulmonem.ca.
Pulmonem Inc.
855, Dieppe Blvd
Dieppe, NB E1A 7R8
CANADA
Media Enquiries
Keelan Green
613-220-2016
green@prospectus.ca